Comments
Loading...

Mersana Therapeutics Analyst Ratings

MRSNNASDAQ
Logo brought to you by Benzinga Data
$0.3350
-0.00490-1.44%
Pre-Market: 4:33 AM EDT
Consensus Rating1
Buy
Highest Price Target1
$14.00
Lowest Price Target1
$1.00
Consensus Price Target1
$6.38

Mersana Therapeutics Analyst Ratings and Price Targets | NASDAQ:MRSN | Benzinga

Mersana Therapeutics Inc has a consensus price target of $6.38 based on the ratings of 9 analysts. The high is $14 issued by SVB Leerink on August 9, 2022. The low is $1 issued by Citigroup on July 28, 2023. The 3 most-recent analyst ratings were released by Citigroup, Baird, and JP Morgan on August 27, 2024, August 14, 2024, and March 19, 2024, respectively. With an average price target of $4.33 between Citigroup, Baird, and JP Morgan, there's an implied 1193.53% upside for Mersana Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Feb
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Citigroup
Baird
JP Morgan
Wedbush
Truist Securities

1calculated from analyst ratings

Analyst Ratings for Mersana Therapeutics

Buy NowGet Alert
02/06/2025Buy Now—William Blair
Andy Hsieh19%
—Initiates → OutperformGet Alert
08/27/2024Buy Now1392.54%Citigroup
Ashiq Mubarack36%
$6 → $5MaintainsBuyGet Alert
08/14/2024Buy Now795.52%Baird
Colleen Kusy34%
$4 → $3MaintainsNeutralGet Alert
03/19/2024Buy Now1392.54%JP Morgan
Brian Cheng38%
→ $5UpgradeUnderweight → NeutralGet Alert
02/29/2024Buy Now1989.55%Wedbush
David Nierengarten61%
$2 → $7UpgradeNeutral → OutperformGet Alert
02/29/2024Buy Now2586.57%Truist Securities
Asthika Goonewardene41%
$9 → $9UpgradeHold → BuyGet Alert
02/29/2024Buy Now1392.54%Baird
Colleen Kusy34%
$1 → $5MaintainsNeutralGet Alert
02/29/2024Buy Now1989.55%Guggenheim
Michael Schmidt51%
→ $7UpgradeNeutral → BuyGet Alert
12/04/2023Buy Now1392.54%Citigroup
Ashiq Mubarack36%
$1 → $5UpgradeNeutral → BuyGet Alert
07/28/2023Buy Now198.51%Citigroup
Ashik Kurian35%
$10 → $1DowngradeBuy → NeutralGet Alert
07/28/2023Buy Now198.51%Baird
Colleen Kusy34%
$7 → $1DowngradeOutperform → NeutralGet Alert
07/27/2023Buy Now497.01%Wedbush
David Nierengarten61%
$12 → $2DowngradeOutperform → NeutralGet Alert
07/27/2023Buy Now—Truist Securities
Asthika Goonewardene41%
—DowngradeBuy → HoldGet Alert
06/16/2023Buy Now2885.07%Citigroup
Ashik Kurian35%
$15 → $10MaintainsBuyGet Alert
06/16/2023Buy Now1392.54%JP Morgan
Brian Cheng38%
$11 → $5DowngradeOverweight → NeutralGet Alert
06/15/2023Buy Now4079.1%Guggenheim
Michael Schmidt51%
→ $14Initiates → BuyGet Alert
05/11/2023Buy Now4377.61%Citigroup
Ashik Kurian35%
$12 → $15MaintainsBuyGet Alert
03/16/2023Buy Now2885.07%JP Morgan
Brian Cheng38%
→ $10UpgradeNeutral → OverweightGet Alert
11/21/2022Buy Now3482.09%Truist Securities
Asthika Goonewardene41%
→ $12Initiates → BuyGet Alert
08/09/2022Buy Now5870.15%Baird
Colleen Kusy34%
$18 → $20MaintainsOutperformGet Alert
08/09/2022Buy Now4079.1%SVB Leerink
Jonathan Chang38%
$13 → $14MaintainsOutperformGet Alert
05/09/2022Buy Now4079.1%SVB Leerink
Jonathan Chang38%
$13 → $14MaintainsOutperformGet Alert

FAQ

Q

What is the target price for Mersana Therapeutics (MRSN) stock?

A

The latest price target for Mersana Therapeutics (NASDAQ:MRSN) was reported by William Blair on February 6, 2025. The analyst firm set a price target for $0.00 expecting MRSN to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Mersana Therapeutics (MRSN)?

A

The latest analyst rating for Mersana Therapeutics (NASDAQ:MRSN) was provided by William Blair, and Mersana Therapeutics initiated their outperform rating.

Q

When was the last upgrade for Mersana Therapeutics (MRSN)?

A

The last upgrade for Mersana Therapeutics Inc happened on March 19, 2024 when JP Morgan raised their price target to $5. JP Morgan previously had an underweight for Mersana Therapeutics Inc.

Q

When was the last downgrade for Mersana Therapeutics (MRSN)?

A

The last downgrade for Mersana Therapeutics Inc happened on July 28, 2023 when Citigroup changed their price target from $10 to $1 for Mersana Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Mersana Therapeutics (MRSN)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mersana Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mersana Therapeutics was filed on February 6, 2025 so you should expect the next rating to be made available sometime around February 6, 2026.

Q

Is the Analyst Rating Mersana Therapeutics (MRSN) correct?

A

While ratings are subjective and will change, the latest Mersana Therapeutics (MRSN) rating was a initiated with a price target of $0.00 to $0.00. The current price Mersana Therapeutics (MRSN) is trading at is $0.34, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch